Susan Pandya M.D., is the Vice President, Clinical Development & Global Head of Oncology LS/LCM at Servier Pharmaceuticals. She leads Servier’s Oncology late stage global clinical development programs which have garnered FDA approvals, including TIBSOVO® (ivosidenib tablets) for cholangiocarcinoma (2021), newly diagnosed AML (2022), R/R MDS (2023), and VORANIGO Grade 2 Glioma (2024). A passionate oncologist with nearly 20 years of drug development experience in academia and the pharmaceutical industry, Susan previously led Oncology Clinical Development programs at Agios Pharmaceuticals and early-stage development at Acceleron Pharma. Earlier, she was a practicing clinician and the Associate Director of the Phase 1 experimental therapeutics program at Beth Israel Deaconess Medical Center in Boston, MA. She earned her M.D. from Tufts University School of Medicine and completed her residency in Internal Medicine and Heme/Onc fellowship at Beth Israel Deaconess Medical Center.